uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted January 16, 2018

Marketers of CellAssure and Cognify Settle FTC Charges of Deceptive Cancer Claims

On January 11, 2018, the FTC announced that CellMark Biopharma, LLC and its CEO, Derek E. Vest have agreed to settle charges that it made false claims about its products, CellAssure and Cognify, which were marketed as treatments for the effects of cancer and chemotherapy such as weight loss, malnutrition, and cognitive dysfunction. 

Join today to unlock all member benefits including full access to all recalls & warnings

Join Now

Join now at